Similar articles for PMID: 17458173

Year	Number of Results
1990	1
1995	1
1998	1
2001	6
2002	8
2003	8
2004	19
2005	11
2006	14
2007	15
2008	25
2009	10
2010	5
2011	3
2012	5
2013	3
2014	3
2015	2
2016	2
2018	2
2024	0

1

Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.

Doehn C, Kausch I, Böhmer T, Sommerauer M, Jocham D. Doehn C, et al. Curr Opin Mol Ther. 2007 Apr;9(2):183-9. Curr Opin Mol Ther. 2007. PMID: 17458173

2

Technology evaluation: CEA-TRICOM, Therion Biologics Corp.

Morse MA. Morse MA. Curr Opin Mol Ther. 2001 Aug;3(4):407-12. Curr Opin Mol Ther. 2001. PMID: 11525565 Clinical Trial.

3

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.

DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. DiPaola RS, et al. J Transl Med. 2006 Jan 3;4:1. doi: 10.1186/1479-5876-4-1. J Transl Med. 2006. PMID: 16390546 Free PMC article.

4

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Kaufman HL, et al. J Clin Oncol. 2004 Jun 1;22(11):2122-32. doi: 10.1200/JCO.2004.08.083. J Clin Oncol. 2004. PMID: 15169798 Clinical Trial.

5

Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.

Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J. Hodge JW, et al. Cancer Res. 2003 Nov 15;63(22):7942-9. Cancer Res. 2003. PMID: 14633725

6

Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.

Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Grosenbach DW, et al. Cancer Res. 2001 Jun 1;61(11):4497-505. Cancer Res. 2001. PMID: 11389081

7

Technology evaluation: PROSTVAC, Therion.

Doehn C, Jocham D. Doehn C, et al. Curr Opin Mol Ther. 2002 Oct;4(5):528-34. Curr Opin Mol Ther. 2002. PMID: 12435056

8

Technology evaluation: Onyvax-P, Onyvax.

Doehn C, Böhmer T, Jocham D. Doehn C, et al. Curr Opin Mol Ther. 2005 Oct;7(5):511-9. Curr Opin Mol Ther. 2005. PMID: 16248287 Review.

9

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Marshall JL, et al. J Clin Oncol. 2005 Feb 1;23(4):720-31. doi: 10.1200/JCO.2005.10.206. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613691 Clinical Trial.

10

Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.

Greiner JW, Zeytin H, Anver MR, Schlom J. Greiner JW, et al. Cancer Res. 2002 Dec 1;62(23):6944-51. Cancer Res. 2002. PMID: 12460911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year